SCHEMBL678497

SCHEMBL678497

[CH2]C(CC)c1ccccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.46
TSHR P16473 2/20 0.39
ACHE P22303 2/20 0.39
ACP3 P15309 1/20 0.36
MC4R P32245 1/20 0.36
CYP2D6 P10635 2/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA2B P18089 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16952697 0.83 TSHR (0.39) ESR1TSHRACHECYP2D6SLC6A2
SCHEMBL16960981 0.79 ESR1 (0.32) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL16957554 0.79 CYP1A2 (0.33) ESR1TSHRCYP2D6CYP3A4LMNA
SCHEMBL8319547 0.78 ESR1 (0.56) ESR1TSHRACHEACP3CYP2D6
SCHEMBL8603731 0.77 TSHR (0.43) TSHRSLC6A2HTR2CHTR2BCYP3A4
SCHEMBL7526920 0.77 ESR1 (0.38) ESR1NPSR1CYP19A1ALDH1A1
SCHEMBL9656285 0.76 ESR1 (0.50) ESR1TSHRACHEACP3MC4R
SCHEMBL31538069 0.76 ESR1 (0.50) ESR1TSHRACHEACP3MC4R
SCHEMBL6547004 0.76 ESR1 (0.50) ESR1TSHRACHEACP3MC4R
SCHEMBL7339680 0.76 TSHR (0.38) TSHRACHEMC4RCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244617-A1 SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE Ortho-McNeil Pharmaceutical, Inc. (US) 2002-10-02 EP claimed
WO-2001047875-A1 SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-07-05 WO claimed
US-5908358-A SHEAR RESISTANCE ACUSHNET COMPANY (US) 1999-06-01 US claimed
EP-0763015-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS ARQULE, INC. (US) 1997-03-19 EP claimed
WO-1995032184-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS ARQULE, INC. (US) 1995-11-30 WO claimed
WO-2023089049-A2 MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2023-05-25 WO disclosed
US-20230131427-A1 FUNGICIDAL COMPOSITIONS SYNGENTA CROP PROTECTION AG (CH) 2023-04-27 US disclosed
US-20180133558-A1 THREE-LAYER-CORE GOLF BALL HAVING HIGHLY-NEUTRALIZED POLYMER OUTER CORE LAYER ACUSHNET COMPANY (US) 2018-05-17 US disclosed
US-20180133559-A1 THREE-LAYER-CORE GOLF BALL HAVING HIGHLY-NEUTRALIZED POLYMER OUTER CORE LAYER ACUSHNET COMPANY (US) 2018-05-17 US disclosed
US-20170209746-A1 THREE-LAYER-CORE GOLF BALL HAVING HIGHLY-NEUTRALIZED POLYMER OUTER CORE LAYER ACUSHNET COMPANY (US) 2017-07-27 US disclosed
US-9616296-B2 Three-layer-core golf ball having highly-neutralized polymer outer core layer ACUSHNET COMPANY (US) 2017-04-11 US disclosed
US-9604105-B2 Highly-neutralized thermoplastic copolymer center for improved multi-layer core golf ball ACUSHNET COMPANY (US) 2017-03-28 US disclosed
WO-1995032184-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS ARQULE, INC. (US) 1995-11-30 WO disclosed
WO-1995018972-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE-BASED MOLECULES HAVING SELECTED PROPERTIES ARQULE, INC. (US) 1995-07-13 WO disclosed
WO-1995018627-A1 METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES ARQULE, INC. (US) 1995-07-13 WO disclosed
WO-1995018186-A1 MODULAR DESIGN AND SYNTHESIS OF AMINIMIDE CONTAINING MOLECULES ARQULE PARTNERS, L.P. (US) 1995-07-06 WO disclosed
WO-1995017903-A1 MODULAR DESIGN AND SYNTHESIS OF OXAZOLONE-DERIVED MOLECULES ARQULE PARTNERS, L.P. (US) 1995-07-06 WO disclosed
WO-1995011894-A1 HISTAMINE H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF THE UNIVERSITY OF TOLEDO (US) 1995-05-04 WO disclosed
EP-0633882-A1 4- 4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF THE UNIVERSITY OF TOLEDO (US) 1995-01-18 EP disclosed
WO-1993020061-A1 4-[4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF THE UNIVERSITY OF TOLEDO (US) 1993-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131427-A1 FUNGICIDAL COMPOSITIONS CYP51A1, CYP4X1, CYP1B1 ESR1 4217/4885TSHR 4252/4885ACHE 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.